"The investigational drug abaloparatideSC subcutaneous may help increase bone mineral density in postmenopausal women with osteoporosis and reduce their risk of vertebral and nonvertebral fractures new industrysponsored research suggests. The results of the prespecified subgroup analysis within the ACTIVE clinical trial will be presented Friday April  at ENDO  the annual meeting of the Endocrine Society in Boston.  According to lead study author Felicia Cosman MD osteoporosis specialist and Medical Director of the Clinical Research Center at Helen Hayes Hospital Senior Clinical Director of the National Osteoporosis Foundation and Professor of Medicine at Columbia University who is a consultant to Radius Health Inc. in Waltham Massachusetts AbaloparatideSC increased bone mineral density in both the spine and hip and reduced the risk of vertebral and nonvertebral fractures consistently in postmenopausal women with osteoporosis regardless of their baseline patient characteristics including age bone mineral density and whether or not they had prior fractures.  The researchers investigated patients enrolled in the randomized doubleblind comparative multicenter international phase  ACTIVE trial to evaluate the efficacy and safety of  micrograms of abaloparatideSC in preventing fractures in otherwise healthy ambulatory postmenopausal women with osteoporosis. Osteoporosis was defined broadly using both BMD criteria as well as recent history of nonvertebral fracture and confirmed prevalent vertebral fracture on xray. Overall  patients between  and  years of age were randomized to one of three treatment arms for  months doubleblind  micrograms of abaloparatideSC blindmatched placebo or openlabel  micrograms of subcutaneous teriparatide an FDAapproved prescription drug known to increase bone density and strength.  At  months abaloparatideSC significantly increased bone mineral density from baseline at the lumbar spine by . the total hip by . and the femoral neck by . compared with placebo. AbaloparatideSC also reduced new vertebral fractures by  nonvertebral fractures by  clinical fractures by  and major osteoporotic fractures by  compared with placebo after  months of treatment. The drug also reduced major osteoporotic fractures by  compared with teriparatide and increased bone density to a greater extent in the hip region compared with teriparatide.  The authors found that the risk of new vertebral or nonvertebral fractures dropped consistently among the participants taking abaloparatideSC irrespective of their baseline risk factors and they found an increase in bone mineral density by abaloparatide in each of the baseline risk subgroups.  The data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.  The study was funded by Radius Health Inc.   Endocrinologists are at the core of solving the most pressing health problems of our time from diabetes and obesity to infertility bone health and hormonerelated cancers. The Endocrine Society is the worlds oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormonerelated conditions.  The Society which is celebrating its centennial in  has more than  members including scientists physicians educators nurses and students in  countries. To learn more about the Society and the field of endocrinology visit our site at http Follow us on Twitter at TheEndoSociety and EndoMedia"